Results 31 to 40 of about 5,996,360 (285)
Cancer statistics for the year 2020: An overview
International Journal of Cancer, 2021 Our study briefly reviews the data sources and methods used in compiling the International Agency for Research on Cancer (IARC) GLOBOCAN cancer statistics for the year 2020 and summarises the main results.
J. Ferlay +6 more
semanticscholar +1 more source
Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma [PDF]
, 2015 The prevalence of global obesity is increasing. Obesity is associated with general cancer-related morbidity and mortality and is a known risk factor for development of specific cancers.
Alfraidi, Albandri +5 more
core +6 more sources
Exosomal αvβ6 integrin is required for monocyte M2 polarization in prostate cancer [PDF]
, 2018 Therapeutic approaches aimed at curing prostate cancer are only partially successful given the occurrence of highly metastatic resistant phenotypes that frequently develop in response to therapies.
Altieri, Dario C. +23 more
core +1 more source
Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer
Cancer Research, 2021 These findings reveal that induction of ferroptosis is a new therapeutic strategy for advanced prostate cancer as a monotherapy and in combination with second-generation antiandrogens.
A. Ghoochani +8 more
semanticscholar +1 more source
Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial [PDF]
, 2016 BACKGROUND: A previous analysis of the placebo arm of the Prostate Cancer Prevention Trial (PCPT) reported 82% overall prevalence of intraprostatic inflammation and identified a link between inflammation and higher-grade prostate cancer and serum PSA ...
Barber, John R +15 more
core +2 more sources
How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer
Prostate Cancer and Prostatic Diseases, 2021 Advanced prostate cancer remains one of the most common and deadly cancers, despite advances in treatment options. Immunotherapy has provided little benefit to a majority of patients, largely due to the immunosuppressive tumor microenvironment that gives
J. Stultz, L. Fong
semanticscholar +1 more source
Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1 [PDF]
, 2018 Aberrant transforming growth factor–β (TGF-β) signaling is a hallmark of the stromal microenvironment in cancer. Dickkopf-3 (Dkk-3), shown to inhibit TGF-β signaling, is downregulated in prostate cancer and upregulated in the stroma in benign prostatic ...
A Dutta +65 more
core +2 more sources
Integrative clinical genomics of advanced prostate cancer.
Cell, 2015 Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of ...
D. Robinson +72 more
semanticscholar +1 more source
Epidemiology of Prostate Cancer
World Journal of Oncology, 2019 Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. Prostate cancer may be asymptomatic at the early stage and often has an indolent course that may require only active surveillance ...
Prashanth Rawla
semanticscholar +1 more source
Molecular Oncology, EarlyView.Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source